additionally , we experienced higher legal costs and increased expenses under our hcv co-promotion agreement with abbvie in 2015 than in the prior year . 59 cash provided by operating activities for the year ended december 31 , 2015 was $ 15.8 million , compared to $ 7.5 million for the year ended december 31 , 2014. as of december 31 , 2015 , we had $ 101.3 million in cash and short term investments , compared to $ 97.9 million at december 31 , 2014 . 2015 developments rapid ebola test early in 2015 , we completed the design of a rapid ebola antigen test using our oraquick ® platform . in june 2015 , we entered into a contract for up to $ 10.4 million in total funding from barda related to our oraquick ® ebola test . the three-year , multi-phased contract included an initial commitment of $ 1.8 million and options for up to an additional $ 8.6 million to fund certain clinical and regulatory activities . in september 2015 , barda exercised an option under the contract to provide $ 7.2 million in additional funding for our oraquick ® ebola test . this funding will be used primarily for clinical and regulatory activities required to request fda 510 ( k ) clearance for this product . funding received under this contract is recorded as other revenue in our consolidated statement of operations as the activities are being performed . in july 2015 , we received a u.s. food and drug administration ( fda ) emergency use authorization ( eua ) for the oraquick ® ebola test . this authorization allows the use of the test for the duration of the u.s. secretary of the department of health and human services ' ( hhs ) august 5 , 2014 declaration regarding the emergency use of in vitro diagnostic tests for the detection of the ebola virus . in march 2016 , we received an eua for use of the ebola test on oral fluid samples collected from cadavers . we have also submitted for pre-qualification of this product with the world health organization . during 2015 , we recognized $ 2.3 million in revenue from sales of this product to the centers for disease control and prevention ( cdc ) for investigational use and field testing in africa . data generated in these clinical and non-clinical studies was used in the application to obtain the eua from the fda . we are also continuing to focus our efforts on securing sustainable product purchase commitments from both government and non-government sources for the oraquick ® ebola rapid antigen test . microbiome product offering during 2015 , an area of focus for our molecular collection business has been the microbiome market , through the offering of our omnigene ® gut product for which we received ce mark approval and completed design validation on a high-throughput automated processing system . several technical manuscripts with academic and biotech groups are in process that will report on the ability of this product to snapshot microbiome communities at the point of collection . we sold our collection kit to over 100 customers and generated approximately $ 539,000 of revenue in 2015. business segments we operate our business within two reportable segments : our osur business , which consists of the development , manufacture and sale of diagnostic products , specimen collection devices , and medical devices , and our dnag or molecular collection systems business , which consists primarily of the development , manufacture and sale of oral fluid collection devices that are used to collect , stabilize , transport , and store samples of genetic material for molecular testing . osur revenues are derived primarily from products sold into the united states and internationally to various clinical laboratories , hospitals , clinics , community-based organizations , public health organizations , distributors , government agencies , physicians ' offices , commercial and industrial entities , retail pharmacies , mass merchandisers and consumers over the internet . dnag revenues result primarily from products sold into the commercial market , which consists of customers engaged in consumer genetics , clinical genetic testing , pharmacogenomics , personalized medicine , microbiome and animal genetic testing , as well as products sold into the academic research market which consists of research laboratories , universities and hospitals . 60 results of operations year ended december 31 , 2015 compared to december 31 , 2014 consolidated net revenues the table below shows a breakdown of total net revenues ( dollars in thousands ) generated by each of our business segments . replace_table_token_5_th consolidated net product revenues increased 6 % to $ 104.5 million in 2015 from $ 98.9 million in 2014 , primarily as a result of higher sales of our molecular collection systems , oraquick ® hcv and intercept ® products . these increases were partially offset by lower sales of our oraquick ® professional hiv and cryosurgical systems products . other revenues were $ 15.3 million in 2015 , of which $ 13.5 million represents exclusivity payments received under our hcv co-promotion agreement with abbvie and $ 1.8 million represents ebola-related funding from barda . other revenues were $ 7.6 million in 2014 , all which represent exclusivity payments from abbvie . consolidated net revenues derived from products sold to customers outside the u.s. were $ 23.2 million and $ 24.2 million , or 19 % and 23 % of consolidated net revenues during the years ended december 31 , 2015 and 2014 , respectively . because the majority of our international sales are denominated in u.s. dollars , the impact of fluctuating foreign currency exchange rates was not material to our total net revenues . net revenues by segment osur segment the table below shows the amount of total net revenues ( dollars in thousands ) generated by our osur segment . story_separator_special_tag the table below shows a breakdown of our total net intercept ® revenues ( dollars in thousands ) generated in each market during 2014 and 2013. replace_table_token_12_th domestic intercept ® sales in 2014 increased to $ 6.1 million compared to $ 5.7 million in 2013 , primarily due to market growth resulting from increased interest in oral fluid testing by customers who previously used alternative specimen types for drug testing and improved domestic employment conditions . international intercept ® sales decreased 70 % to $ 149,000 in 2014 from $ 500,000 in 2013 largely due to the absence of purchases by a uk distributor who began selling its own competing oral specimen collection device in 2012. sales to this distributor were $ 316,000 in 2013. cryosurgical systems market sales of our cryosurgical systems products ( which includes both the physicians ' office and otc markets ) increased 7 % to $ 15.5 million in 2014 from $ 14.5 million in 2013 . 67 the table below shows a breakdown of our total net cryosurgical systems revenues ( dollars in thousands ) generated in each market during 2014 and 2013. replace_table_token_13_th sales of our histofreezer ® product in the domestic professional market increased 12 % to $ 6.8 million in 2014 , compared to $ 6.0 million in 2013. this increase is largely due to higher sales by one of our distributors to teaching hospitals , physician offices , and the military . this increase also reflects below normal sales in early 2013 , resulting from higher distributor purchases in the fourth quarter of 2012 in advance of a price increase implemented in january 2013. the current year increase in net revenues was negatively impacted by the merger of our two largest distributors , who began selling a private label cryosurgical product in direct competition with our histofreezer ® product in 2014. during 2014 , international sales of histofreezer ® decreased to $ 693,000 , compared to $ 1.4 million in the same period of the prior year . our long-term supply agreement for the histofreezer ® product with a contract manufacturer terminated in late 2013 , and that former supplier has since begun promoting a competing product similar to histofreezer ® . in order to remain competitive with this new product , we have decreased the per unit sales price of our histofreezer ® product in certain international markets . in addition , we experienced delivery problems and inventory shortages as we transitioned to a new manufacturer of our international histofreezer ® product line . in the fourth quarter of 2014 , we launched our wart removal product in the u.s. retail market through private labeling with a large pharmacy chain . sales related to this product were $ 108,000. sales of our international otc cryosurgical products during 2014 increased 14 % to $ 8.0 million compared to $ 7.0 million in 2013 , largely due to higher sales to our european distributor , partially offset by lower sales to our latin american distributor . sales to our european distributor increased to $ 4.8 million , compared to $ 3.6 million during 2013 , primarily due to the launch of our product into new geographic territories and new market segments in europe . sales to our latin american distributor decreased to $ 3.0 million , compared to $ 3.3 million in 2013 , reflecting lower sales into brazil , partially offset by an increase in sales into mexico . insurance risk assessment market sales to the insurance risk assessment market decreased 7 % to $ 3.7 million in 2014 from $ 3.9 million in 2013 , as a result of reduced demand in the domestic life insurance market , resulting from the adoption by some underwriters of a simplified issue policy , pursuant to which testing for risk factors is replaced by having applicants respond to a questionnaire about their behaviors . other revenues other revenues were $ 7.6 million in 2014 and represent the recognition of exclusivity revenues under our hcv co-promotion agreement with abbvie . other revenues in 2013 were $ 623,000 and represent royalties paid on domestic outsales of merck 's otc cryosurgical wart removal product , pursuant to a license and settlement agreement which expired in august 2013 . 68 dnag segment molecular collection systems net molecular collection systems revenues , which primarily represent sales of our oragene ® product line , increased 17 % to $ 23.8 million in 2014 from $ 20.4 million in 2013. sales of oragene ® in the commercial market increased approximately 9 % in 2014 , primarily as a result of overall market growth and increased use of our oragene ® product in pharmacogenomics testing . sales of oragene ® in the academic market increased 35 % largely due to orders placed by two new international customers as well as higher sales to one of the company 's larger existing academic customers . sales to dnag 's largest commercial customer decreased approximately $ 3.4 million in 2014. sales to dnag 's other customers grew 48 % in the current year and substantially offset the lower sales to this large customer . consolidated operating results consolidated gross margin was 63 % in 2014 compared to 59 % in 2013. this increase was largely due to the $ 7.6 million of other revenues associated with our abbvie agreement , as well as a more favorable product mix driven largely by increased dnag sales to higher margin customers . consolidated operating loss decreased by $ 7.4 million to $ 4.8 million in 2014 , compared $ 12.2 million in 2013. the lower operating loss was primarily due to the higher licensing and product development revenues and lower hiv otc sales and marketing expenses in 2014 , partially offset by a $ 2.8 million reduction in contract termination payments received from roche during 2014. operating income ( loss ) by segment osur segment osur 's gross margin was 60 % in 2014 compared to

liquidity and capital resources replace_table_token_14_th our cash and short-term investment balances increased to $ 101.3 million at december 31 , 2015 from $ 97.9 million at december 31 , 2014. our working capital increased to $ 111.5 million at december 31 , 2015 from $ 104.8 million at december 31 , 2014. during 2015 , we generated $ 15.8 million in cash from our operating activities . our net income of $ 8.2 million was increased by non-cash stock-based compensation expense of $ 6.0 million , depreciation and amortization expense of $ 5.7 million , and other non-cash charges of $ 605,000. a $ 2.3 million decrease in inventory balances largely associated with our oraquick ® hcv product also contributed to cash generated in 2015. also contributing to cash provided by operations in 2015 was a net increase in deferred revenue of $ 1.7 million , which represents the receipt of cash payments from abbvie reduced by the amounts ratably recognized in revenue during the period . uses of cash in operating activities during 2015 included a $ 3.7 million increase in accounts receivable resulting from a higher level of product orders placed near the end of the year ; a $ 2.6 million decrease in accounts payable largely associated with a decrease in expenses related to the abbvie agreement ; a $ 1.4 million increase in prepaid expenses and other assets largely associated with the new canadian office lease and the buy-out of our royalty obligation under one of our license agreements ; and a $ 992,000 decrease in accrued expenses and other liabilities largely associated with a decrease in our royalty obligations . we used a net amount of $ 6.7 million in investing activities during 2015 to purchase $ 26.9 million in short-term investments and $ 3.7 million to acquire property and equipment . these payments were offset by proceeds received from the maturities of short-term investments of $ 23.9 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources replace_table_token_14_th our cash and short-term investment balances increased to $ 101.3 million at december 31 , 2015 from $ 97.9 million at december 31 , 2014. our working capital increased to $ 111.5 million at december 31 , 2015 from $ 104.8 million at december 31 , 2014. during 2015 , we generated $ 15.8 million in cash from our operating activities . our net income of $ 8.2 million was increased by non-cash stock-based compensation expense of $ 6.0 million , depreciation and amortization expense of $ 5.7 million , and other non-cash charges of $ 605,000. a $ 2.3 million decrease in inventory balances largely associated with our oraquick ® hcv product also contributed to cash generated in 2015. also contributing to cash provided by operations in 2015 was a net increase in deferred revenue of $ 1.7 million , which represents the receipt of cash payments from abbvie reduced by the amounts ratably recognized in revenue during the period . uses of cash in operating activities during 2015 included a $ 3.7 million increase in accounts receivable resulting from a higher level of product orders placed near the end of the year ; a $ 2.6 million decrease in accounts payable largely associated with a decrease in expenses related to the abbvie agreement ; a $ 1.4 million increase in prepaid expenses and other assets largely associated with the new canadian office lease and the buy-out of our royalty obligation under one of our license agreements ; and a $ 992,000 decrease in accrued expenses and other liabilities largely associated with a decrease in our royalty obligations . we used a net amount of $ 6.7 million in investing activities during 2015 to purchase $ 26.9 million in short-term investments and $ 3.7 million to acquire property and equipment . these payments were offset by proceeds received from the maturities of short-term investments of $ 23.9 million .
```    
 Suspicious Activity Report : additionally , we experienced higher legal costs and increased expenses under our hcv co-promotion agreement with abbvie in 2015 than in the prior year . 59 cash provided by operating activities for the year ended december 31 , 2015 was $ 15.8 million , compared to $ 7.5 million for the year ended december 31 , 2014. as of december 31 , 2015 , we had $ 101.3 million in cash and short term investments , compared to $ 97.9 million at december 31 , 2014 . 2015 developments rapid ebola test early in 2015 , we completed the design of a rapid ebola antigen test using our oraquick ® platform . in june 2015 , we entered into a contract for up to $ 10.4 million in total funding from barda related to our oraquick ® ebola test . the three-year , multi-phased contract included an initial commitment of $ 1.8 million and options for up to an additional $ 8.6 million to fund certain clinical and regulatory activities . in september 2015 , barda exercised an option under the contract to provide $ 7.2 million in additional funding for our oraquick ® ebola test . this funding will be used primarily for clinical and regulatory activities required to request fda 510 ( k ) clearance for this product . funding received under this contract is recorded as other revenue in our consolidated statement of operations as the activities are being performed . in july 2015 , we received a u.s. food and drug administration ( fda ) emergency use authorization ( eua ) for the oraquick ® ebola test . this authorization allows the use of the test for the duration of the u.s. secretary of the department of health and human services ' ( hhs ) august 5 , 2014 declaration regarding the emergency use of in vitro diagnostic tests for the detection of the ebola virus . in march 2016 , we received an eua for use of the ebola test on oral fluid samples collected from cadavers . we have also submitted for pre-qualification of this product with the world health organization . during 2015 , we recognized $ 2.3 million in revenue from sales of this product to the centers for disease control and prevention ( cdc ) for investigational use and field testing in africa . data generated in these clinical and non-clinical studies was used in the application to obtain the eua from the fda . we are also continuing to focus our efforts on securing sustainable product purchase commitments from both government and non-government sources for the oraquick ® ebola rapid antigen test . microbiome product offering during 2015 , an area of focus for our molecular collection business has been the microbiome market , through the offering of our omnigene ® gut product for which we received ce mark approval and completed design validation on a high-throughput automated processing system . several technical manuscripts with academic and biotech groups are in process that will report on the ability of this product to snapshot microbiome communities at the point of collection . we sold our collection kit to over 100 customers and generated approximately $ 539,000 of revenue in 2015. business segments we operate our business within two reportable segments : our osur business , which consists of the development , manufacture and sale of diagnostic products , specimen collection devices , and medical devices , and our dnag or molecular collection systems business , which consists primarily of the development , manufacture and sale of oral fluid collection devices that are used to collect , stabilize , transport , and store samples of genetic material for molecular testing . osur revenues are derived primarily from products sold into the united states and internationally to various clinical laboratories , hospitals , clinics , community-based organizations , public health organizations , distributors , government agencies , physicians ' offices , commercial and industrial entities , retail pharmacies , mass merchandisers and consumers over the internet . dnag revenues result primarily from products sold into the commercial market , which consists of customers engaged in consumer genetics , clinical genetic testing , pharmacogenomics , personalized medicine , microbiome and animal genetic testing , as well as products sold into the academic research market which consists of research laboratories , universities and hospitals . 60 results of operations year ended december 31 , 2015 compared to december 31 , 2014 consolidated net revenues the table below shows a breakdown of total net revenues ( dollars in thousands ) generated by each of our business segments . replace_table_token_5_th consolidated net product revenues increased 6 % to $ 104.5 million in 2015 from $ 98.9 million in 2014 , primarily as a result of higher sales of our molecular collection systems , oraquick ® hcv and intercept ® products . these increases were partially offset by lower sales of our oraquick ® professional hiv and cryosurgical systems products . other revenues were $ 15.3 million in 2015 , of which $ 13.5 million represents exclusivity payments received under our hcv co-promotion agreement with abbvie and $ 1.8 million represents ebola-related funding from barda . other revenues were $ 7.6 million in 2014 , all which represent exclusivity payments from abbvie . consolidated net revenues derived from products sold to customers outside the u.s. were $ 23.2 million and $ 24.2 million , or 19 % and 23 % of consolidated net revenues during the years ended december 31 , 2015 and 2014 , respectively . because the majority of our international sales are denominated in u.s. dollars , the impact of fluctuating foreign currency exchange rates was not material to our total net revenues . net revenues by segment osur segment the table below shows the amount of total net revenues ( dollars in thousands ) generated by our osur segment . story_separator_special_tag the table below shows a breakdown of our total net intercept ® revenues ( dollars in thousands ) generated in each market during 2014 and 2013. replace_table_token_12_th domestic intercept ® sales in 2014 increased to $ 6.1 million compared to $ 5.7 million in 2013 , primarily due to market growth resulting from increased interest in oral fluid testing by customers who previously used alternative specimen types for drug testing and improved domestic employment conditions . international intercept ® sales decreased 70 % to $ 149,000 in 2014 from $ 500,000 in 2013 largely due to the absence of purchases by a uk distributor who began selling its own competing oral specimen collection device in 2012. sales to this distributor were $ 316,000 in 2013. cryosurgical systems market sales of our cryosurgical systems products ( which includes both the physicians ' office and otc markets ) increased 7 % to $ 15.5 million in 2014 from $ 14.5 million in 2013 . 67 the table below shows a breakdown of our total net cryosurgical systems revenues ( dollars in thousands ) generated in each market during 2014 and 2013. replace_table_token_13_th sales of our histofreezer ® product in the domestic professional market increased 12 % to $ 6.8 million in 2014 , compared to $ 6.0 million in 2013. this increase is largely due to higher sales by one of our distributors to teaching hospitals , physician offices , and the military . this increase also reflects below normal sales in early 2013 , resulting from higher distributor purchases in the fourth quarter of 2012 in advance of a price increase implemented in january 2013. the current year increase in net revenues was negatively impacted by the merger of our two largest distributors , who began selling a private label cryosurgical product in direct competition with our histofreezer ® product in 2014. during 2014 , international sales of histofreezer ® decreased to $ 693,000 , compared to $ 1.4 million in the same period of the prior year . our long-term supply agreement for the histofreezer ® product with a contract manufacturer terminated in late 2013 , and that former supplier has since begun promoting a competing product similar to histofreezer ® . in order to remain competitive with this new product , we have decreased the per unit sales price of our histofreezer ® product in certain international markets . in addition , we experienced delivery problems and inventory shortages as we transitioned to a new manufacturer of our international histofreezer ® product line . in the fourth quarter of 2014 , we launched our wart removal product in the u.s. retail market through private labeling with a large pharmacy chain . sales related to this product were $ 108,000. sales of our international otc cryosurgical products during 2014 increased 14 % to $ 8.0 million compared to $ 7.0 million in 2013 , largely due to higher sales to our european distributor , partially offset by lower sales to our latin american distributor . sales to our european distributor increased to $ 4.8 million , compared to $ 3.6 million during 2013 , primarily due to the launch of our product into new geographic territories and new market segments in europe . sales to our latin american distributor decreased to $ 3.0 million , compared to $ 3.3 million in 2013 , reflecting lower sales into brazil , partially offset by an increase in sales into mexico . insurance risk assessment market sales to the insurance risk assessment market decreased 7 % to $ 3.7 million in 2014 from $ 3.9 million in 2013 , as a result of reduced demand in the domestic life insurance market , resulting from the adoption by some underwriters of a simplified issue policy , pursuant to which testing for risk factors is replaced by having applicants respond to a questionnaire about their behaviors . other revenues other revenues were $ 7.6 million in 2014 and represent the recognition of exclusivity revenues under our hcv co-promotion agreement with abbvie . other revenues in 2013 were $ 623,000 and represent royalties paid on domestic outsales of merck 's otc cryosurgical wart removal product , pursuant to a license and settlement agreement which expired in august 2013 . 68 dnag segment molecular collection systems net molecular collection systems revenues , which primarily represent sales of our oragene ® product line , increased 17 % to $ 23.8 million in 2014 from $ 20.4 million in 2013. sales of oragene ® in the commercial market increased approximately 9 % in 2014 , primarily as a result of overall market growth and increased use of our oragene ® product in pharmacogenomics testing . sales of oragene ® in the academic market increased 35 % largely due to orders placed by two new international customers as well as higher sales to one of the company 's larger existing academic customers . sales to dnag 's largest commercial customer decreased approximately $ 3.4 million in 2014. sales to dnag 's other customers grew 48 % in the current year and substantially offset the lower sales to this large customer . consolidated operating results consolidated gross margin was 63 % in 2014 compared to 59 % in 2013. this increase was largely due to the $ 7.6 million of other revenues associated with our abbvie agreement , as well as a more favorable product mix driven largely by increased dnag sales to higher margin customers . consolidated operating loss decreased by $ 7.4 million to $ 4.8 million in 2014 , compared $ 12.2 million in 2013. the lower operating loss was primarily due to the higher licensing and product development revenues and lower hiv otc sales and marketing expenses in 2014 , partially offset by a $ 2.8 million reduction in contract termination payments received from roche during 2014. operating income ( loss ) by segment osur segment osur 's gross margin was 60 % in 2014 compared to

